Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015
Author: Price, T.
Thavaneswaran, S.
Burge, M.
Segelov, E.
Haller, D.
Punt, C.
Arnold, D.
Karapetis, C.
Tebbutt, N.
Pavlakis, N.
Gibbs, P.
Shapiro, J.
Citation: Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care, 2016; 16(5):557-571
Publisher: Taylor and Francis
Issue Date: 2016
ISSN: 1473-7140
Statement of
Timothy J Price, Subotheni Thavaneswaran, Matthew Burge, Eva Segelov, Daniel G Haller, Cornelis JA Punt, Dirk Arnold, Christos S Karapetis, Niall C Tebbutt, Nick Pavlakis, Peter Gibbs and Jeremy D Shapiro
Abstract: The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice.
Keywords: Colorectal cancer
Rights: © 2016 Informa UK Limited, trading as Taylor & Francis Group
DOI: 10.1586/14737140.2016.1170594
Appears in Collections:Aurora harvest 7
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.